

## Media Contact:

Emily Denney West Global Communications +1-610-594-3035 Emily.Denney@westpharma.com

## Construction Commences at West Waterford, Ireland Manufacturing Facility

**Waterford, Ireland** — July 18, 2015 – <u>West Pharmaceutical Services, Inc.</u> (NYSE: WST), a global leader in innovative packaging components and drug delivery systems, can confirm that construction commenced on July 14, 2015, in Waterford, Ireland for the company's new pharmaceutical component manufacturing facility.

The 95,000 square foot (approximately 8,800 square meter) facility will be situated at a 44-acre industrial site at Knockhouse on Old Kilmeaden Road in Waterford. Civil work has commenced this week. The construction of the building shell and the external infrastructure work to support roads, water and electricity are the primary focus over the upcoming months.

At the same time as the construction, work on the excavation of the remains of a ringfort continues on site. This excavation was always part of the overall plan for the site and does not delay the construction. The excavations are being carried out by West in partnership with the Waterford City and County Council, following a process of archaeological investigation and assessment of the site which commenced in 1998, when the land was owned by the IDA. West is following through on these plans and working closely with the authorities. The company has consulted with the National Monuments Service of the Department of Arts, Heritage and the Gaeltacht, who also issued the license for this work. Once complete, the results of the excavations will be made available to the general public through a formal report.

The Waterford facility will manufacture packaging components for insulin injector cartridges and other high-value packaging components for injectable drugs, to meet increasing customer demand. The company intends to employ approximately 150 people in engineering, production and other positions by the commencement of operations in late 2018.

## About West

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2014 sales of \$1.42 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.



## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the federal securities laws which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as "may," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," or "potential" or the negative of these words and phrases or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect West's good faith beliefs, assumptions and expectations, they are not guarantees of future performance. Furthermore, except as required by law, West disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in periodic reports under the Securities Exchange Act of 1934, as amended, filed by West from time to time with the Securities and Exchange Commission.

###